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and during therapy Hb appear to be associated with fatigue, poorer 
quality of life (QoL), and increased hospitalization. 
Methods: This is a multi-centre prospective cohort study in completely 
resected primary NSCLC patients who are scheduled to receive 4-6 
cycles of platinum-based adjuvant chemotherapy. Patients are to be 
followed throughout their entire treatment period to assess anemia 
rates and document anemia management, as well as identify prognostic 
factors for anemia development. Long-term outcome assessments are 
currently ongoing.
Results: As part of an interim analysis, 115 patients enrolled into the 
study were assessed. Mean age was 63.5 years and 52% of patients 
were female. Mean baseline hemoglobin (Hb) was 132.8 g/L. Less 
than 20% patients had a Hb of ≤ 120 g/L at the onset of adjuvant 
chemotherapy. During chemotherapy, 101 patients (87.8%) developed 
moderate anemia as deﬁned a priori in the protocol as a Hb ≤120 g/L 
or a Hb drop of ≥ 20 g/L. Furthermore, 40 patients (34.8%) had a Hb 
of < 100 g/L and 56 patients (48.7%) had a Hb of 100-120 g/L during 
chemotherapy. Time to development of moderate anemia was observed 
in greater than 75% of patients by the end of Cycle 1. As data collec-
tion is ongoing, data relating to anemia treatment on study is limited 
to 90 patients. In this subset, 19 patients (21.1%) received red blood 
cell transfusions, while only 13 patients (14.4%) reported receiving an 
erythropoietic agent. 
Conclusions: In an interim analysis of 115 NSCLC patients receiv-
ing adjuvant chemotherapy, it was observed that 88% of the patients 
developed anemia as deﬁned above, with a statistically strict conﬁdence 
interval of 12%. Time to development of anemia in the majority of 
the patients occurred early in their chemotherapy regimen. As such, 
erythropoietic intervention in this patient population may prove beneﬁ-
cial. Final analyses will include data from approximately 130 patients, 
including transfusion use, chemotherapy data and QoL data. Future 
research is required to conﬁrm the impact of anemia management on 
patient outcomes. 
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Background: Despite recent advances in the treatment of pts with 
non-small cell lung cancer (NSCLC), the outcome continues to be poor. 
Only about 3% of all adult oncology pts enroll in clinical trials com-
pared to approximately 50% of pediatric pts. The proportion of adult 
pts enrolled in clinical trials is low, even in tertiary cancer centers. It is 
critical to understand the barriers for accrual to clinical trials. 
Methods: We reviewed the outpatient charts of all pts with NSCLC 
referred to the thoracic medical oncology group at our institution from 
1/1/2006 to 12/31/2006. Available and appropriate clinical trials were 
presented to the pts routinely and reasons for non-enrollment were 
documented. We collected information on histology, stage, performance 
status (PS), and co-morbid conditions. Appropriate studies at the time 
of initial consultation were noted from the cancer center database. 
Results: Of 272 consecutive patient charts reviewed, 13 pts (4.8%) did 
not require therapy and 26 pts (9.6%) had already initiated therapy at 
the time of the consultation. Of the remaining 233 evaluable pts, 51 pts 
(21.9%) were not enrolled because of lack of available appropriate clin-
ical trials at the time of initial consultation, the most common reason 
being lack of available studies for adjuvant therapy. Twenty-four pts 
(10.3%) enrolled onto a clinical trial. The most common reasons for not 
being enrolled in a clinical trial included: ineligibility due to poor PS 
(32 pts, 13.7%), need for emergent radiotherapy (20 pts, 8.6%), patient 
refusal (14 pts, 6.0%), geographic issues (10 pts, 4.3%), and insurance 
issues (10 pts, 4.3%). Three pts (1.3%) were lost to follow-up. 
Conclusion: Poor performance status is the most common reason for 
non-enrollment onto a clinical trial. 
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Background: Cutaneous toxicities due to E or G are common and 
reversible adverse effects. In the two large randomized trials with E 
(Shepherd F et al, NEJM 2005) and G (Thatcher N et al, Lancet 2005) 
skin rash toxicity incidence seems different between the two drugs: all 
grades (gr) were observed in 76% and 37% of patients (pts), gr 3-4 in 
9% and 2% respectively. The aim of this study was to assess the inci-
dence of the most common toxicities occurred in a cohort of pts treated 
with E or G in the same period of time and evaluated by the same 
medical staff according to the Common Toxicity Criteria version 3.0.
Methods: From May 2005 to July 2006, 47 pts suitable for a treat-
ment with an EGFR inhibitor were evaluated for their eligibility in an 
expanded access program (EAP) with E 150 mg/day. Pts ineligible for 
the EAP (16) were treated with G 250 mg/day in a compassionate-use 
program. Fifteen pts were treated with G at progression after E.
Results: Toxicities (all gr, gr 3/3-4) for E vs G consisted in: acneiform 
rash (64 vs 25%, 13 vs 0%), rash/desquamation (83 vs 19%, 12 vs 0%), 
pruritus (38 vs 16%, 6 vs 0%), dry skin (48 vs 32%, 3 vs 0%), nail 
changes (15 vs 6%, 3 vs 0%), diarrhea (54 vs 19%). When pts were 
treated with both E and G the toxicities (all gr, gr 3/3-4) observed were: 
acneiform rash (93 vs 20%, 27 vs 0%), rash/desquamation (100 vs 
20%, 20 vs 0%), pruritus (41 vs 13%, 7 vs 0%), dry skin (54 vs 27%, 7 
vs 0%), nail changes (27 vs 7%, 7 vs 0%), diarrhea (53 vs 7%).
Conclusions: Our data suggest that there are less cutaneous adverse 
effects with G. This difference may be probably attributed to the dose 
of E three times greater than the G dose.
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